Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 7 May 2009, Vol. 113, No. 19, pp. 4484.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westgren, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westgren, M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

TRANSPLANTATION

Comment on Liuba et al, page 4790

Intrauterine transplantation

Magnus Westgren

KAROLINSKA UNIVERSITY HOSPITAL

In this issue of Blood, Liuba and colleagues provide important results in support of intrauterine transplantation for fetuses with X-SCID.

Using a congenic mouse model, Liuba and colleagues show that lymphoid-primed multipotent progenitors are superior to hematopoietic stem cells in providing rapid lymphoid reconstitution following intrauterine transplantation, with sustained polyclonal B-cell production.1 Furthermore, they clearly demonstrate that in this model, intrauterine transplantation results in superior B-cell and T-cell reconstitution of X-linked severe combined immune deficiency (X-SCID) patients as compared to delaying transplantion until the neonatal or adolescent age range. Although caution must be executed when extrapolating these data to humans, the study is very interesting and important in regard to the potential for providing a cure for these children before birth.

Since Touraine et al published the first instance of intrauterine transplantation in a human fetus affected by bare lymphocyte syndrome (BLS) in 1989,2 we are aware of 4 X-SCID intrauterine transplantation cases.35 All these fetuses survived and were chimeric at birth. Despite favorable results, the intrauterine approach was criticized by several authorities in this field who claimed that this approach did not offer any advantage over postnatal transplantation. The main arguments against intrauterine transplantation were that the fetal invasive procedure carried a certain additional risk, and if the mother was used as a donor, there might be an increased risk for graft-versus-host disease (GVHD), a condition which cannot be treated prenatally. Conversely, promoters of intrauterine transplantation claimed that reconstitution of the immune system before birth results in reduced susceptibility to infections in the neonatal period, and to an improved psychosocial situation for the family. Other potential advantages for an intrauterine approach include cost savings and a reduced risk of GVHD in the fetal environment.

Not surprisingly, these varied opinions on the risk-benefit balance of intrauterine transplantation were expressed by representatives from different fields of medicine. Those arguing against are usually transplantation clinicians comfortable with postnatal transplantation procedures, and those arguing in favor of intrauterine transplantation usually represent specialists in fetal medicine and fetal surgery. Thus, a consensus has been difficult to reach and fetal transplantation has not been widely adopted, despite the fact that cases treated in utero had outcomes comparable with the best reported with postnatal transplantation.

So far, 46 cases of intrauterine human transplantation for various indications have been reported.6 In 1 case, the fetus did not survive the procedure. A 2% complication rate is in agreement with the risk calculation performed by Liuba et al. Likely, the complication rate can be reduced further using a 22-gauge needle and modern ultrasonic guidance.

The lack of relevant animal models allowing direct comparisons between prenatal and postnatal transplantation has hampered further development in this field. The work by Liuba et al adds important information. It seems that the earlier the reconstitution of the immunologic system takes place, the better the results. This needs to be considered by those involved in the care of mothers carrying fetuses potentially affected by X-SCID.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Liuba K, Pronk CJH, Stott SRW, Jacobsen S-EW. Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors. Blood. 2009;113:4790–4798.[Abstract/Free Full Text]

  2. Touraine JL, Raudrant D, Royo C, et al. In-utero transplantation of stem cells in bare lymphocyte syndrome. Lancet. 1989;1:1382.[Medline] [Order article via Infotrieve]

  3. Flake AW, Roncarolo MG, Puck JM, et al. Treatment of X-linked severe combined immunodeficiency bu in utero transplantation of paternal bone marrow. N Engl J Med. 1996;335:1806–1810.[Free Full Text]

  4. Lanfranchi A, Neva A, Tettoni K, et al. In utero transplantation of parental CD 34+ cells in patients affected byb primary immunodeficiency. BMT. 1998;21:S127.

  5. Westgren M, Ringden O, Bartmann P, et al. Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. Am J Obstet Gynecol. 2002;187:475–482.[CrossRef][Medline] [Order article via Infotrieve]

  6. Tiblad E, Westgren M. Fetal stem cell transplantation. Best Pract Res Clin Obstet Gynecol. 2008;22:189–201.[CrossRef]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors
Karina Liuba, Cornelis J. H. Pronk, Simon R. W. Stott, and Sten-Eirik W. Jacobsen
Blood 2009 113: 4790-4798. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westgren, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westgren, M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020